# SAMPLE CODING

## Acute Myeloid Leukemia

<table>
<thead>
<tr>
<th>TYPE</th>
<th>CODE</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C92.00</td>
<td>Acute myeloblastic leukemia, not having achieved remission</td>
</tr>
<tr>
<td></td>
<td>C92.01</td>
<td>Acute myeloblastic leukemia, in remission</td>
</tr>
<tr>
<td></td>
<td>C92.50</td>
<td>Acute myelomonocytic leukemia, not having achieved remission</td>
</tr>
<tr>
<td></td>
<td>C92.51</td>
<td>Acute myelomonocytic leukemia, in remission</td>
</tr>
<tr>
<td></td>
<td>C92.60</td>
<td>Acute myeloid leukemia with 11q23-abnormality, not having achieved remission</td>
</tr>
<tr>
<td></td>
<td>C92.61</td>
<td>Acute myeloid leukemia with 11q23-abnormality, in remission</td>
</tr>
<tr>
<td></td>
<td>C92.A0</td>
<td>Acute myeloid leukemia with multilineage dysplasia, not having achieved remission</td>
</tr>
<tr>
<td></td>
<td>C92.A1</td>
<td>Acute myeloid leukemia with multilineage dysplasia, in remission</td>
</tr>
<tr>
<td></td>
<td>C93.00</td>
<td>Acute monoblastic/monocytic leukemia, not having achieved remission</td>
</tr>
<tr>
<td></td>
<td>C93.01</td>
<td>Acute monoblastic/monocytic leukemia, in remission</td>
</tr>
<tr>
<td></td>
<td>C94.00</td>
<td>Acute erythroid leukemia, not having achieved remission</td>
</tr>
<tr>
<td></td>
<td>C94.01</td>
<td>Acute erythroid leukemia, in remission</td>
</tr>
<tr>
<td></td>
<td>C94.20</td>
<td>Acute megakaryoblastic leukemia, not having achieved remission</td>
</tr>
<tr>
<td></td>
<td>C94.21</td>
<td>Acute megakaryoblastic leukemia, in remission</td>
</tr>
</tbody>
</table>

**Diagnosis: ICD-10-CM**

ICD-10-CM = International Classification of Diseases, 10th Revision, Clinical Modification; NDC = National Drug Code.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

For additional safety information, please see the full Prescribing Information and Medication Guide.
Acute Myeloid Leukemia (cont)

<table>
<thead>
<tr>
<th>TYPE</th>
<th>CODE</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10-digit</td>
<td>11-digit</td>
</tr>
<tr>
<td>0074-0579-28</td>
<td>00074-0579-28</td>
<td>Starting pack (contains 4 weekly wallet blister packs)</td>
</tr>
<tr>
<td>0074-0561-14</td>
<td>00074-0561-14</td>
<td>10 mg wallet (14 x 10 mg tablets)</td>
</tr>
<tr>
<td>0074-0566-07</td>
<td>00074-0566-07</td>
<td>50 mg wallet (7 x 50 mg tablets)</td>
</tr>
<tr>
<td>0074-0576-22</td>
<td>00074-0576-22</td>
<td>100 mg bottle (120 x 100 mg tablets)</td>
</tr>
<tr>
<td>0074-0576-34</td>
<td>00074-0576-34</td>
<td>100 mg bottle (180 x 100 mg tablets)</td>
</tr>
<tr>
<td>0074-0561-11</td>
<td>00074-0561-11</td>
<td>10 mg unit dose (2 x 10 mg tablets)</td>
</tr>
<tr>
<td>0074-0566-11</td>
<td>00074-0566-11</td>
<td>50 mg unit dose (1 x 50 mg tablet)</td>
</tr>
<tr>
<td>0074-0576-11</td>
<td>00074-0576-11</td>
<td>100 mg unit dose (1 x 100 mg tablet)</td>
</tr>
</tbody>
</table>

Drug: NDC
Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.

ICD-10-CM = International Classification of Diseases, 10th Revision, Clinical Modification; NDC = National Drug Code.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

INDICATIONS & IMPORTANT SAFETY INFORMATION

Indications
VENCLEXTA is indicated:
- For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

This indication is approved under accelerated approval based on response rates. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Important Safety Information

Contraindication
- Concomitant use of VENCLEXTA with strong CYP3A inhibitors at initiation and during ramp-up phase is contraindicated in patients with CLL/SLL due to the potential for increased risk of tumor lysis syndrome (TLS).

Tumor Lysis Syndrome
- Tumor lysis syndrome, including fatal events and renal failure requiring dialysis, has occurred in patients with high tumor burden when treated with VENCLEXTA.
- In patients with CLL who followed the current (5 week) dose ramp-up and the TLS prophylaxis and monitoring measures, the rate of TLS was 2% in the VENCLEXTA CLL monotherapy studies. The rate of TLS remained consistent with VENCLEXTA in combination with obinutuzumab or rituximab. With a 2 to 3 week dose ramp-up and higher starting dose in patients with CLL/SLL, the TLS rate was 13% and included deaths and renal failure.

For additional safety information, please see the full Prescribing Information and Medication Guide.
Important Safety Information (cont)

Tumor Lysis Syndrome (cont)

- VENCLEXTA poses a risk for TLS at initiation and during the ramp-up phase. Changes in blood chemistries consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose of VENCLEXTA and at each dose increase.
- Patients should be assessed for TLS risk, including evaluation of tumor burden and comorbidities, and should receive appropriate prophylaxis for TLS, including hydration and anti-hyperuricemics. Reduced renal function further increases the risk. Monitor blood chemistries and manage abnormalities promptly. Interrupt dosing if needed. Employ more intensive measures (IV hydration, frequent monitoring, hospitalization) as overall risk increases.
- Concomitant use of VENCLEXTA with strong or moderate CYP3A inhibitors or P-gp inhibitors may increase the risk of TLS at initiation and during the ramp-up phase, and requires dose adjustment due to increases in VENCLEXTA exposure.

Neutropenia

- In patients with CLL, Grade 3 or 4 neutropenia developed in 63% to 64% of patients and Grade 4 neutropenia developed in 31% to 33% of patients treated with VENCLEXTA in combination and monotherapy studies. Febrile neutropenia occurred in 4% to 6% of patients treated with VENCLEXTA in combination and monotherapy studies.
- In patients with AML, baseline neutrophil counts worsened in 97% to 100% of patients treated with VENCLEXTA in combination with azacitidine or decitabine or low-dose cytarabine. Neutropenia can recur with subsequent cycles of therapy.
- Monitor complete blood counts throughout the treatment period. Interrupt dosing or reduce dose for severe neutropenia. Consider supportive measures including antimicrobials for signs of infection and use of growth factors (e.g., G-CSF).

Infections

- Fatal and serious infections such as pneumonia and sepsis have occurred in patients treated with VENCLEXTA. Monitor patients closely for signs and symptoms of infection and treat promptly. Withhold VENCLEXTA for Grade 3 and higher infection.

Immunization

- Do not administer live attenuated vaccines prior to, during, or after treatment with VENCLEXTA until B-cell recovery occurs. Advise patients that vaccinations may be less effective.

Embryo-Fetal Toxicity

- VENCLEXTA may cause embryo-fetal harm when administered to a pregnant woman. Advise females of reproductive potential to avoid pregnancy during treatment.

Increased Mortality in Patients with Multiple Myeloma when VENCLEXTA is Added to Bortezomib and Dexamethasone

- In a randomized trial (BELLINI; NCT02755597) in patients with relapsed or refractory multiple myeloma, the addition of VENCLEXTA to bortezomib plus dexamethasone, a use for which VENCLEXTA is not indicated, resulted in increased mortality. Treatment of patients with multiple myeloma with VENCLEXTA in combination with bortezomib plus dexamethasone is not recommended outside of controlled clinical trials.

Adverse Reactions

- In patients with CLL receiving combination therapy with obinutuzumab, serious adverse reactions were most often due to febrile neutropenia and pneumonia (5% each). The most common adverse reactions (≥20%) of any grade were neutropenia (60%), diarrhea (28%), and fatigue (21%).
- In patients with CLL receiving combination therapy with rituximab, the most frequent serious adverse reaction (≥5%) was pneumonia (9%). The most common adverse reactions (≥20%) of any grade were neutropenia (65%), diarrhea (40%), upper respiratory tract infection (39%), fatigue (22%), cough (22%), and nausea (21%).
- In patients with CLL/SLL receiving monotherapy, the most frequent serious adverse reactions (≥5%) were pneumonia (9%), febrile neutropenia (5%), and sepsis (5%). The most common adverse reactions (≥20%) of any grade were neutropenia (50%), diarrhea (43%), nausea (42%), upper respiratory tract infection (36%), anemia (33%), fatigue (32%), thrombocytopenia (29%), musculoskeletal pain (29%), edema (22%), and cough (22%).
- In patients with AML receiving combination therapy with azacitidine, the most frequent serious adverse reactions (≥5%) were febrile neutropenia, pneumonia (excluding fungal), sepsis (excluding fungal), respiratory failure, and multiple organ dysfunction syndrome. The most common adverse reactions (≥30%) of any grade were nausea (58%), diarrhea (54%), constipation (49%), neutropenia (49%), thrombocytopenia (49%), hemorrhage (46%), peripheral edema (46%), vomiting (40%), fatigue (36%), febrile neutropenia (36%), rash (33%), and anemia (30%).
Important Safety Information (cont)

Adverse Reactions (cont)

• In patients with AML receiving combination therapy with decitabine, the most frequent serious adverse reactions (≥5%) were febrile neutropenia, sepsis (excluding fungal), pneumonia (excluding fungal), diarrhea, fatigue, cellulitis, and localized infection. The most common adverse reactions (≥30%) of any grade were febrile neutropenia (69%), constipation (62%), fatigue (62%), thrombocytopenia (54%), abdominal pain (46%), dizziness (46%), hemorrhage (46%), nausea (46%), pneumonia (excluding fungal) (46%), sepsis (excluding fungal) (46%), cough (38%), diarrhea (38%), neutropenia (38%), back pain (31%), hypotension (31%), myalgia (31%), oropharyngeal pain (31%), peripheral edema (31%), pyrexia (31%), and rash (31%).

• In patients with AML receiving combination therapy with low-dose cytarabine, the most frequent serious adverse reactions (≥5%) were febrile neutropenia, sepsis (excluding fungal), hemorrhage, pneumonia (excluding fungal), and device-related infection. The most common adverse reactions (≥30%) of any grade were nausea (64%), thrombocytopenia (59%), hemorrhage (49%), febrile neutropenia (46%), neutropenia (46%), diarrhea (44%), fatigue (44%), constipation (33%), and dyspnea (31%).

Drug Interactions

• Concomitant use with a strong or moderate CYP3A inhibitor or a P-gp inhibitor increases VENCLEXTA exposure, which may increase VENCLEXTA toxicities, including the risk of TLS. Adjust VENCLEXTA dosage and closely monitor patients for signs of VENCLEXTA toxicities. Resume the VENCLEXTA dosage that was used prior to concomitant use of a strong or moderate CYP3A inhibitor or a P-gp inhibitor 2 to 3 days after discontinuation of the inhibitor.

• Patients should avoid grapefruit products, Seville oranges, and starfruit during treatment as they contain inhibitors of CYP3A.

• Avoid concomitant use of strong or moderate CYP3A inducers.

• Avoid concomitant use of VENCLEXTA with a P-gp substrate. If concomitant use is unavoidable, separate dosing of the P-gp substrate at least 6 hours before VENCLEXTA.

• Monitor international normalized ratio (INR) closely in patients receiving warfarin.

Lactation

• Advise nursing women to discontinue breastfeeding during treatment with VENCLEXTA.

Females and Males of Reproductive Potential

• Advise females of reproductive potential to use effective contraception during treatment with VENCLEXTA and for at least 30 days after the last dose.

• Based on findings in animals, male fertility may be compromised by treatment with VENCLEXTA.

Hepatic Impairment

• Reduce the dose of VENCLEXTA for patients with severe hepatic impairment (Child-Pugh C); monitor these patients more closely for signs of toxicity. No dose adjustment is recommended for patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment.

For additional safety information, please see the full Prescribing Information and Medication Guide.
Chronic Lymphocytic Leukemia

**Sample Coding**

### Chronic Lymphocytic Leukemia

<table>
<thead>
<tr>
<th>TYPE</th>
<th>CODE</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis: ICD-10-CM</td>
<td>C91.10</td>
<td>Chronic lymphocytic leukemia of B-cell type not having achieved remission</td>
</tr>
<tr>
<td></td>
<td>C91.11</td>
<td>Chronic lymphocytic leukemia of B-cell type in remission</td>
</tr>
<tr>
<td></td>
<td>C91.12</td>
<td>Chronic lymphocytic leukemia of B-cell type in relapse</td>
</tr>
</tbody>
</table>

**Drug: NDC**

Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.

<table>
<thead>
<tr>
<th>10-digit</th>
<th>11-digit</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>0074-0579-28</td>
<td>00074-0579-28</td>
<td>Starting pack (contains 4 weekly wallet blister packs)</td>
</tr>
<tr>
<td>0074-0561-14</td>
<td>00074-0561-14</td>
<td>10 mg wallet (14 x 10 mg tablets)</td>
</tr>
<tr>
<td>0074-0566-07</td>
<td>00074-0566-07</td>
<td>50 mg wallet (7 x 50 mg tablets)</td>
</tr>
<tr>
<td>0074-0576-22</td>
<td>00074-0576-22</td>
<td>100 mg bottle (120 x 100 mg tablets)</td>
</tr>
<tr>
<td>0074-0576-34</td>
<td>00074-0576-34</td>
<td>100 mg bottle (180 x 100 mg tablets)</td>
</tr>
<tr>
<td>0074-0561-11</td>
<td>00074-0561-11</td>
<td>10 mg unit dose (2 x 10 mg tablets)</td>
</tr>
<tr>
<td>0074-0566-11</td>
<td>00074-0566-11</td>
<td>50 mg unit dose (1 x 50 mg tablet)</td>
</tr>
<tr>
<td>0074-0576-11</td>
<td>00074-0576-11</td>
<td>100 mg unit dose (1 x 100 mg tablet)</td>
</tr>
</tbody>
</table>

**INDICATIONS & IMPORTANT SAFETY INFORMATION**

**Indications**

VENCLEXTA is indicated:

- For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

This indication is approved under accelerated approval based on response rates. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

For additional safety information, please see the full Prescribing Information and Medication Guide.
Important Safety Information

Contraindication

• Concomitant use of VENCLEXTA with strong CYP3A inhibitors at initiation and during ramp-up phase is contraindicated in patients with CLL/SLL due to the potential for increased risk of tumor lysis syndrome (TLS).

Tumor Lysis Syndrome

• Tumor lysis syndrome, including fatal events and renal failure requiring dialysis, has occurred in patients with high tumor burden when treated with VENCLEXTA.

• In patients with CLL who followed the current (5 week) dose ramp-up and the TLS prophylaxis and monitoring measures, the rate of TLS was 2% in the VENCLEXTA CLL monotherapy studies. The rate of TLS remained consistent with VENCLEXTA in combination with obinutuzumab or rituximab. With a 2 to 3 week dose ramp-up and higher starting dose in patients with CLL/SLL, the TLS rate was 13% and included deaths and renal failure.

• VENCLEXTA poses a risk for TLS at initiation and during the ramp-up phase. Changes in blood chemistries consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose of VENCLEXTA and at each dose increase.

• Patients should be assessed for TLS risk, including evaluation of tumor burden and comorbidities, and should receive appropriate prophylaxis for TLS, including hydration and anti-hyperuricemics. Reduced renal function further increases the risk. Monitor blood chemistries and manage abnormalities promptly. Interrupt dosing if needed. Employ more intensive measures (IV hydration, frequent monitoring, hospitalization) as overall risk increases.

• Concomitant use of VENCLEXTA with strong or moderate CYP3A inhibitors or P-gp inhibitors may increase the risk of TLS at initiation and during the ramp-up phase, and requires dose adjustment due to increases in VENCLEXTA exposure.

Neutropenia

• In patients with CLL, Grade 3 or 4 neutropenia developed in 63% to 64% of patients and Grade 4 neutropenia developed in 31% to 33% of patients treated with VENCLEXTA in combination and monotherapy studies. Febrile neutropenia occurred in 4% to 6% of patients treated with VENCLEXTA in combination and monotherapy studies.

• In patients with AML, baseline neutrophil counts worsened in 97% to 100% of patients treated with VENCLEXTA in combination with azacitidine or decitabine or low-dose cytarabine. Neutropenia can recur with subsequent cycles of therapy.

• Monitor complete blood counts throughout the treatment period. Interrupt dosing or reduce dose for severe neutropenia. Consider supportive measures including antimicrobials for signs of infection and use of growth factors (e.g., G-CSF).

Infections

• Fatal and serious infections such as pneumonia and sepsis have occurred in patients treated with VENCLEXTA. Monitor patients closely for signs and symptoms of infection and treat promptly. Withhold VENCLEXTA for Grade 3 and higher infection.

Immunization

• Do not administer live attenuated vaccines prior to, during, or after treatment with VENCLEXTA until B-cell recovery occurs. Advise patients that vaccinations may be less effective.

Embryo-Fetal Toxicity

• VENCLEXTA may cause embryo-fetal harm when administered to a pregnant woman. Advise females of reproductive potential to avoid pregnancy during treatment.

Increased Mortality in Patients with Multiple Myeloma when VENCLEXTA is Added to Bortezomib and Dexamethasone

• In a randomized trial (BELLINI; NCT02755597) in patients with relapsed or refractory multiple myeloma, the addition of VENCLEXTA to bortezomib plus dexamethasone, a use for which VENCLEXTA is not indicated, resulted in increased mortality. Treatment of patients with multiple myeloma with VENCLEXTA in combination with bortezomib plus dexamethasone is not recommended outside of controlled clinical trials.

Adverse Reactions

• In patients with CLL receiving combination therapy with obinutuzumab, serious adverse reactions were most often due to febrile neutropenia and pneumonia (5% each). The most common adverse reactions (≥20%) of any grade were neutropenia (60%), diarrhea (28%), and fatigue (21%).

• In patients with CLL receiving combination therapy with rituximab, the most frequent serious adverse reaction (≥5%) was pneumonia (9%). The most common adverse reactions (≥20%) of any grade were neutropenia (65%), diarrhea (40%), upper respiratory tract infection (39%), fatigue (22%), cough (22%), and nausea (21%).

For additional safety information, please see the full Prescribing Information and Medication Guide.
Important Safety Information (cont)

Adverse Reactions (cont)

• In patients with CLL/SLL receiving monotherapy, the most frequent serious adverse reactions (≥5%) were pneumonia (9%), febrile neutropenia (5%), and sepsis (5%). The most common adverse reactions (≥20%) of any grade were neutropenia (50%), diarrhea (43%), nausea (42%), upper respiratory tract infection (36%), anemia (33%), fatigue (32%), thrombocytopenia (29%), musculoskeletal pain (29%), edema (22%), and cough (22%).

• In patients with AML receiving combination therapy with azacitidine, the most frequent serious adverse reactions (≥5%) were febrile neutropenia, pneumonia (excluding fungal), sepsis (excluding fungal), respiratory failure, and multiple organ dysfunction syndrome. The most common adverse reactions (≥30%) of any grade were nausea (58%), diarrhea (54%), constipation (49%), anemia (46%), thrombocytopenia (46%), peripheral edema (46%), vomiting (40%), fatigue (36%), febrile neutropenia (36%), rash (33%), and anemia (30%).

• In patients with AML receiving combination therapy with decitabine, the most frequent serious adverse reactions (≥5%) were febrile neutropenia, sepsis (excluding fungal), pneumonia (excluding fungal), diarrhea, fatigue, cellulitis, and localized infection. The most common adverse reactions (≥30%) of any grade were febrile neutropenia (69%), constipation (62%), fatigue (62%), thrombocytopenia (54%), abdominal pain (46%), dizziness (46%), hemorrhage (46%), nausea (46%), pneumonia (excluding fungal) (46%), sepsis (excluding fungal) (46%), cough (38%), diarrhea (38%), neutropenia (38%), back pain (31%), hypotension (31%), myalgia (31%), oropharyngeal pain (31%), peripheral edema (31%), pyrexia (31%), and rash (31%).

• In patients with AML receiving combination therapy with low-dose cytarabine, the most frequent serious adverse reactions (≥5%) were febrile neutropenia, sepsis (excluding fungal), pneumonia (excluding fungal), diarrhea, fatigue, and neutropenia. The most common adverse reactions (≥30%) of any grade were nausea (64%), thrombocytopenia (59%), hemorrhage (49%), fever (46%), febrile neutropenia (46%), neutropenia (46%), diarrhea (44%), fatigue (44%), constipation (33%), and dyspnea (31%).

Drug Interactions

• Concomitant use with a strong or moderate CYP3A inhibitor or a P-gp inhibitor increases VENCLEXTA exposure, which may increase VENCLEXTA toxicities, including the risk of TLS. Adjust VENCLEXTA dosage and closely monitor patients for signs of VENCLEXTA toxicities. Resume the VENCLEXTA dosage that was used prior to concomitant use of a strong or moderate CYP3A inhibitor or a P-gp inhibitor 2 to 3 days after discontinuation of the inhibitor.

• Patients should avoid grapefruit products, Seville oranges, and starfruit during treatment as they contain inhibitors of CYP3A.

• Avoid concomitant use of strong or moderate CYP3A inducers.

• Avoid concomitant use of VENCLEXTA with a P-gp substrate. If concomitant use is unavoidable, separate dosing of the P-gp substrate at least 6 hours before VENCLEXTA.

• Monitor international normalized ratio (INR) closely in patients receiving warfarin.

Lactation

• Advise nursing women to discontinue breastfeeding during treatment with VENCLEXTA.

Females and Males of Reproductive Potential

• Advise females of reproductive potential to use effective contraception during treatment with VENCLEXTA and for at least 30 days after the last dose.

• Based on findings in animals, male fertility may be compromised by treatment with VENCLEXTA.

Hepatic Impairment

• Reduce the dose of VENCLEXTA for patients with severe hepatic impairment (Child-Pugh C); monitor these patients more closely for signs of toxicity. No dose adjustment is recommended for patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment.

For additional safety information, please see the full Prescribing Information and Medication Guide.
# SAMPLE CODING

## Small Lymphocytic Lymphoma

<table>
<thead>
<tr>
<th>TYPE</th>
<th>CODE</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C83.00</td>
<td>Small cell B-cell lymphoma, unspecified site</td>
</tr>
<tr>
<td></td>
<td>C83.01</td>
<td>Small cell B-cell lymphoma, lymph nodes of head, face, and neck</td>
</tr>
<tr>
<td></td>
<td>C83.02</td>
<td>Small cell B-cell lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C83.03</td>
<td>Small cell B-cell lymphoma, intra-abdominal lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C83.04</td>
<td>Small cell B-cell lymphoma, lymph nodes of axilla and upper limb</td>
</tr>
<tr>
<td></td>
<td>C83.05</td>
<td>Small cell B-cell lymphoma, lymph nodes of inguinal region and lower limb</td>
</tr>
<tr>
<td></td>
<td>C83.06</td>
<td>Small cell B-cell lymphoma, intrapelvic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>C83.07</td>
<td>Small cell B-cell lymphoma, spleen</td>
</tr>
<tr>
<td></td>
<td>C83.08</td>
<td>Small cell B-cell lymphoma, lymph nodes of multiple sites</td>
</tr>
<tr>
<td></td>
<td>C83.09</td>
<td>Small cell B-cell lymphoma, extranodal and solid organ sites</td>
</tr>
</tbody>
</table>

**Diagnosis: ICD-10-CM**

**Drug: NDC**

*Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.*

<table>
<thead>
<tr>
<th>10-digit</th>
<th>11-digit</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>0074-0579-28</td>
<td>00074-0579-28</td>
<td>Starting pack (contains 4 weekly wallet blister packs)</td>
</tr>
<tr>
<td>0074-0561-14</td>
<td>00074-0561-14</td>
<td>10 mg wallet (14 x 10 mg tablets)</td>
</tr>
<tr>
<td>0074-0566-07</td>
<td>00074-0566-07</td>
<td>50 mg wallet (7 x 50 mg tablets)</td>
</tr>
<tr>
<td>0074-0576-22</td>
<td>00074-0576-22</td>
<td>100 mg bottle (120 x 100 mg tablets)</td>
</tr>
<tr>
<td>0074-0576-34</td>
<td>00074-0576-34</td>
<td>100 mg bottle (180 x 100 mg tablets)</td>
</tr>
<tr>
<td>0074-0561-11</td>
<td>00074-0561-11</td>
<td>10 mg unit dose (2 x 10 mg tablets)</td>
</tr>
<tr>
<td>0074-0566-11</td>
<td>00074-0566-11</td>
<td>50 mg unit dose (1 x 50 mg tablet)</td>
</tr>
<tr>
<td>0074-0576-11</td>
<td>00074-0576-11</td>
<td>100 mg unit dose (1 x 100 mg tablet)</td>
</tr>
</tbody>
</table>

ICD-10-CM = International Classification of Diseases, 10th Revision, Clinical Modification; NDC = National Drug Code.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

For additional safety information, please see the full Prescribing Information and Medication Guide.
INDICATIONS & IMPORTANT SAFETY INFORMATION

Indication
VENCLEXTA is indicated:
• For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Important Safety Information

Contraindication
• Concomitant use of VENCLEXTA with strong CYP3A inhibitors at initiation and during ramp-up phase is contraindicated in patients with CLL/SLL due to the potential for increased risk of tumor lysis syndrome (TLS).

Tumor Lysis Syndrome
• Tumor lysis syndrome, including fatal events and renal failure requiring dialysis, has occurred in patients with high tumor burden when treated with VENCLEXTA.
• In patients with CLL who followed the current (5 week) dose ramp-up and the TLS prophylaxis and monitoring measures, the rate of TLS was 2% in the VENCLEXTA CLL monotherapy studies. The rate of TLS remained consistent with VENCLEXTA in combination with obinutuzumab or rituximab. With a 2- to 3-week dose ramp-up and higher starting dose in patients with CLL/SLL, the TLS rate was 13% and included deaths and renal failure.
• VENCLEXTA poses a risk for TLS at initiation and during the ramp-up phase. Changes in blood chemistries consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose of VENCLEXTA and at each dose increase.
• Patients should be assessed for TLS risk, including evaluation of tumor burden and comorbidities, and should receive appropriate prophylaxis for TLS, including hydration and anti-hyperuricemics. Reduced renal function further increases the risk. Monitor blood chemistries and manage abnormalities promptly. Interrupt dosing if needed. Employ more intensive measures (IV hydration, frequent monitoring, hospitalization) as overall risk increases.
• Concomitant use of VENCLEXTA with strong or moderate CYP3A inhibitors or P-gp inhibitors may increase the risk of TLS at initiation and during the ramp-up phase, and requires dose adjustment due to increases in VENCLEXTA exposure.

Neutropenia
• In patients with CLL, Grade 3 or 4 neutropenia developed in 63% to 64% of patients and Grade 4 neutropenia developed in 31% to 33% of patients treated with VENCLEXTA in combination and monotherapy studies. Febrile neutropenia occurred in 4% to 6% of patients treated with VENCLEXTA in combination and monotherapy studies.
• Monitor complete blood counts throughout the treatment period. Interrupt dosing or reduce dose for severe neutropenia. Consider supportive measures including antimicrobials for signs of infection and use of growth factors (e.g., G-CSF).

Infections
• Fatal and serious infections such as pneumonia and sepsis have occurred in patients treated with VENCLEXTA. Monitor patients closely for signs and symptoms of infection and treat promptly. Withhold VENCLEXTA for Grade 3 and higher infection.

Immunization
• Do not administer live attenuated vaccines prior to, during, or after treatment with VENCLEXTA until B-cell recovery occurs. Advise patients that vaccinations may be less effective.

Embryo-Fetal Toxicity
• VENCLEXTA may cause embryo-fetal harm when administered to a pregnant woman. Advise females of reproductive potential to avoid pregnancy during treatment.

Increased Mortality in Patients with Multiple Myeloma when VENCLEXTA is Added to Bortezomib and Dexamethasone
• In a randomized trial (BELLINI; NCT02755597) in patients with relapsed or refractory multiple myeloma, the addition of VENCLEXTA to bortezomib plus dexamethasone, a use for which VENCLEXTA is not indicated, resulted in increased mortality. Treatment of patients with multiple myeloma with VENCLEXTA in combination with bortezomib plus dexamethasone is not recommended outside of controlled clinical trials.

For additional safety information, please see the full Prescribing Information and Medication Guide.
Important Safety Information (cont)

Adverse Reactions

• In patients with CLL receiving combination therapy with obinutuzumab, serious adverse reactions were most often due to febrile neutropenia and pneumonia (5% each). The most common adverse reactions (≥20%) of any grade were neutropenia (60%), diarrhea (28%), and fatigue (21%).

• In patients with CLL receiving combination therapy with rituximab, the most frequent serious adverse reaction (≥5%) was pneumonia (9%). The most common adverse reactions (≥20%) of any grade were neutropenia (65%), diarrhea (40%), upper respiratory tract infection (39%), fatigue (22%), cough (22%), and nausea (21%).

• In patients with CLL/SLL receiving monotherapy, the most frequent serious adverse reactions (≥5%) were pneumonia (9%), febrile neutropenia (5%), and sepsis (5%). The most common adverse reactions (≥20%) of any grade were neutropenia (50%), diarrhea (43%), nausea (42%), upper respiratory tract infection (36%), anemia (33%), fatigue (32%), thrombocytopenia (29%), musculoskeletal pain (29%), edema (22%), and cough (22%).

Drug Interactions

• Concomitant use with a strong or moderate CYP3A inhibitor or a P-gp inhibitor increases VENCLEXTA exposure, which may increase VENCLEXTA toxicities, including the risk of TLS. Adjust VENCLEXTA dosage and closely monitor patients for signs of VENCLEXTA toxicities. Resume the VENCLEXTA dosage that was used prior to concomitant use of a strong or moderate CYP3A inhibitor or a P-gp inhibitor 2 to 3 days after discontinuation of the inhibitor.

• Patients should avoid grapefruit products, Seville oranges, and starfruit during treatment as they contain inhibitors of CYP3A.

• Avoid concomitant use of strong or moderate CYP3A inducers.

• Avoid concomitant use of VENCLEXTA with a P-gp substrate. If concomitant use is unavoidable, separate dosing of the P-gp substrate at least 6 hours before VENCLEXTA.

• Monitor international normalized ratio (INR) closely in patients receiving warfarin.

Lactation

• Advise nursing women to discontinue breastfeeding during treatment with VENCLEXTA.

Females and Males of Reproductive Potential

• Advise females of reproductive potential to use effective contraception during treatment with VENCLEXTA and for at least 30 days after the last dose.

• Based on findings in animals, male fertility may be compromised by treatment with VENCLEXTA.

Hepatic Impairment

• Reduce the dose of VENCLEXTA for patients with severe hepatic impairment (Child-Pugh C); monitor these patients more closely for signs of toxicity. No dose adjustment is recommended for patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment.

For additional safety information, please see the full Prescribing Information and Medication Guide.